Optometrists in Bolivar, MO Accepting Medicare

8 Optometrists found. Showing 1 - 8

Kemp Family Eye Care, Llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 325 S Main Ave, Bolivar, MO 65613 Phone: 417-777-9000    Fax: 417-777-9003

Wesley Don Kemp, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 325 S Main Ave, Bolivar, MO 65613 Phone: 417-777-9000    Fax: 417-777-9003

Steven Bartholomew Od Llc Optometrist Medicare: Medicare Enrolled Practice Location: 2451 S Springfield Ave, Bolivar, MO 65613 Phone: 417-777-7662    Fax: 417-777-6917

Dr. Shay Andrea Sechler, OD Optometrist Medicare: Medicare Enrolled Practice Location: 626 S Springfield Ave, Bolivar, MO 65613 Phone: 417-839-7724

Vision Source Bolivar Optometrist Medicare: Medicare Enrolled Practice Location: 680 E Aldrich Road, Bolivar, MO 65613 Phone: 417-777-9000    Fax: 417-777-9003

Mr. Richard Lane Nutt, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1111 E Cambridge St, Bolivar, MO 65613 Phone: 417-326-6001

Dr. Laura Beth Montgomery, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 680 Aldrich Rd, Bolivar, MO 65613 Phone: 417-777-9000    Fax: 417-777-9000

Southwest Ozark Optometric Physicians Inc Optometrist Medicare: Medicare Enrolled Practice Location: 2451 S Springfield Ave, Bolivar, MO 65613 Phone: 417-777-7662    Fax: 417-777-6917

News Archive

FDA Advisory Committees vote against approval of Acurox NDA

Acura Pharmaceuticals, Inc. and King Pharmaceuticals®, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Anesthetic and Life Support Drugs and Drug Safety and Risk Management Committees voted that they do not have enough evidence to support the approval of the New Drug Application (NDA) for Acurox® (oxycodone HCl and niacin) Tablets for the treatment of moderate to severe pain, considering the deterrent effects of niacin as well as the potential deterrent effects of the other features specific to Acurox®.

Media reporting can reduce impact of infectious disease outbreaks

At the first sign of a disease pandemic, public health officials should begin strongly communicating about the extent of the outbreak and the steps that can be taken by the public to avoid infection. That's the recommendation of two mathematical biologists who have modified the most widely used infectious disease transmission model to account for the impact of news media coverage.

Pilot study assesses antibody response to third COVID-19 vaccine dose in kidney transplant recipients

A pilot study has begun to assess the antibody response to a third dose of an authorized COVID-19 mRNA vaccine in kidney transplant recipients who did not respond to two doses of the Moderna or Pfizer-BioNTech COVID-19 vaccine.

AHIP supports bipartisan health care reform that covers all Americans

"We strongly support comprehensive, bipartisan health care reform that covers all Americans, improves quality, and puts the health care system on an affordable, sustainable path. Health plans have proposed guaranteed coverage, elimination of pre-existing condition exclusions, and no longer basing premiums on health status or gender. Experience in the states has shown that market reforms need to paired with universal coverage to make health care as affordable as possible.

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company's two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014.

Read more Medical News

› Verified 4 days ago